Abstract:Objective This study aimed to evaluate the impact of in-utero illicit fentanyl exposure on neonatal outcomes, including neonatal opioid withdrawal syndrome (NOWS), length of stay (LOS), and treatment requirements. Study Design This study was conducted from March 2020 to December 2022, and focused on neonates born to mothers with opioid use or opioid use disorder (OUD). Maternal opioid use was identified through self-report or umbilical cord tissue (UCT) testing. Severe NOWS was defined as cases requiring pharmacological treatment. Statistical analyses included univariate comparisons, logistic regression, and generalized linear models to assess the associations between fentanyl exposure and neonatal outcomes. Results Forty-seven percent (75/159) of infants had in-utero fentanyl exposure. Fentanyl-positive mothers were older, 31 ± 5 years, compared to non-fentanyl mothers, 29 ± 5, p = 0.01. They were also less likely to receive prenatal care ( p < 0.01) and had a higher number of polysubstance used, 5 ± 1 compared to non-fentanyl mothers, 3 ± 1, p < 0.01. Overall, infants exposed to fentanyl had a higher incidence of severe NOWS (odds ratio = 5.8, 95% confidence interval [CI]: 2.49–12.95, p < 0.01) and required earlier NOWS treatment initiation, 1 ± 1 day compared to non-exposed infants 3 ± 2 days, p < 0.01. In adjusted analysis, fentanyl exposure was associated with a nearly three-fold increased risk of NOWS (Mantel–Haenszel combined relative risk = 2.98, 95% CI: 1.94–4.57). Furthermore, fentanyl exposure led to longer LOS, with a 40% increase for preterm neonates ( p < 0.01) and a 63% increase for full-term neonates ( p < 0.01). Additionally, there was a significant correlation between log fentanyl concentration in umbilical cord tissue and cumulative morphine dose required for NOWS treatment, p = 0.001. Conclusion Prenatal illicit fentanyl exposure is an independent and strong risk factor for severe NOWS presentation in newborns requiring extended hospital stays. Key Points Illicit fentanyl is increasingly recognized as a major driver of opioid-related substance use disorders during pregnancy, often occurring alongside polysubstance use. Significant prenatal exposure to opioids is a well-established risk factor for neonatal opioid withdrawal syndrome. The recent rise in illicit fentanyl use has heightened these concerns. Both preterm and term infants are at risk for severe withdrawal symptoms following prenatal exposure to illicit fentanyl. This study was approved by the IRB of the UTHSC. No consent form was required. Received: 06 September 2024 Accepted: 09 October 2024 Article published online: 29 October 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

The Development of Disinhibited Social Engagement Disorder: A Case Report on the Psychiatric Implications of Prenatal Fentanyl Use

Illicit Fentanyl in the Prenatal Period: A Significant Emerging Risk for Neonatal Opioid Withdrawal Syndrome

Opioid exposure in gestation, postnatal adversity, and preschool-age cognitive functioning

Prenatal Exposures, Diagnostic Outcomes, and Life Experiences of Children and Youths with Fetal Alcohol Spectrum Disorder

Effects of neonatal fentanyl on late adolescent opioid-mediated behavior

Fifty Years of Research on Prenatal Substances: Lessons Learned for the Opioid Epidemic

Association of fentanyl with neurodevelopmental outcomes in very-low-birth-weight infants

Prenatal Substance Exposure and Infant Discharge Placement: Results From the ACT NOW Study

Prenatal methadone exposure and child developmental outcomes in 2-year-old children

The effects of prenatal exposure to opioids on early childhood development: context matters most

Neurobehavioral Characterization of Perinatal Oxycodone-Exposed Offspring in Early Adolescence

Health outcomes in children with prenatal opioid exposure with and without neonatal abstinence syndrome in the first seven years of life: An observational cohort study

Developmental consequences of fetal exposure to drugs: what we know and what we still must learn

Prenatal exposure to opioids and neurodevelopment in infancy and childhood: A systematic review

Inhibition of post-lanosterol biosynthesis by fentanyl: potential implications for Fetal Fentanyl Syndrome (FFS)

The immediate and long-term effects of prenatal opioid exposure

Consequences of Parental Opioid Exposure on Neurophysiology, Behavior, and Health in the Next Generations

Transcriptomic profiling of reward and sensory brain areas in perinatal fentanyl exposed juvenile mice

Prenatal buprenorphine/naloxone exposure and neonatal neurobehavioral functioning: A preliminary report

Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome

Prenatal nicotine exposure during pregnancy results in adverse neurodevelopmental alterations and neurobehavioral deficits